|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Alexander_Zehnder
|
|
gptkbp:collaboratedWith
|
gptkb:Bayer
gptkb:GSK
gptkb:Bill_&_Melinda_Gates_Foundation
|
|
gptkbp:competitor
|
gptkb:Moderna
gptkb:Pfizer
gptkb:GSK
gptkb:Sanofi
gptkb:BioNTech
|
|
gptkbp:country
|
gptkb:Germany
|
|
gptkbp:developedBy
|
CVnCoV (COVID-19 vaccine candidate)
|
|
gptkbp:focus
|
therapeutics
vaccine development
mRNA technology
|
|
gptkbp:founded
|
2000
|
|
gptkbp:founder
|
gptkb:Ingmar_Hoerr
|
|
gptkbp:fundedBy
|
gptkb:European_Parliament
gptkb:German_government
gptkb:Coalition_for_Epidemic_Preparedness_Innovations_(CEPI)
|
|
gptkbp:headquarters_location
|
gptkb:Tübingen
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CureVac
|
|
gptkbp:industry
|
gptkb:biotechnology
gptkb:drug
|
|
gptkbp:IPODate
|
August 2020
|
|
gptkbp:languageOfWork
|
gptkb:German
English
|
|
gptkbp:legalForm
|
Aktiengesellschaft (AG)
|
|
gptkbp:marketCap
|
varies (publicly traded)
|
|
gptkbp:notableEvent
|
received €300 million investment from German government in 2020
entered partnership with GSK in 2020
COVID-19 vaccine candidate failed phase 3 trial in 2021
|
|
gptkbp:notablePerson
|
gptkb:Florian_von_der_Mülbe
gptkb:Hans-Georg_Rammensee
gptkb:Steve_Pascolo
|
|
gptkbp:notableProduct
|
gptkb:CVnCoV
second-generation COVID-19 vaccine (in development)
|
|
gptkbp:numberOfEmployees
|
~600
|
|
gptkbp:officeLocation
|
Friedrich-Miescher-Str. 15, 72076 Tübingen, Germany
|
|
gptkbp:parentOrganization
|
none
|
|
gptkbp:patent
|
mRNA stabilization technology
|
|
gptkbp:publiclyTraded
|
yes
|
|
gptkbp:researchArea
|
infectious diseases
oncology
rare diseases
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
2020
|
|
gptkbp:stockSymbol
|
gptkb:CVAC
|
|
gptkbp:subsidiary
|
gptkb:CureVac_Real_Estate_GmbH
|
|
gptkbp:website
|
https://www.curevac.com/
|
|
gptkbp:bfsParent
|
gptkb:World_Economic_Forum_Technology_Pioneer
|
|
gptkbp:bfsLayer
|
6
|